ABL Bio to unveil clinical data on two bispecific antibody immuno-oncology drugs at ESMO
Predicted impact: Medium
Clinical data on two bispecific antibody drugs at ESMO; pipeline news for a firm with tiny revenue.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.